When managing antiplatelet therapy in patients requiring surgery, you must balance thrombotic risk against bleeding risk. This patient presents a classic dilemma: recent stroke requiring dual antiplatelet therapy (DAPT) versus urgent cancer surgery with bleeding concerns.

The correct approach is D - continue aspirin and hold clopidogrel for 5 days. Here's why: aspirin provides essential cardiovascular protection with relatively modest bleeding risk, while clopidogrel (a P2Y12 inhibitor) significantly increases surgical bleeding and can be safely interrupted. Clopidogrel's antiplatelet effects last 5-7 days after discontinuation, so stopping it 5 days preoperatively allows platelet function recovery while maintaining some dual protection until surgery.

A is wrong because stopping both agents creates unnecessary thrombotic risk, especially given his recent stroke. Seven days may be excessive for aspirin cessation. B is incorrect because anticoagulation with LMWH doesn't replicate antiplatelet effects and actually increases bleeding risk when combined with surgery. Bridging is typically used for anticoagulation, not antiplatelet therapy. C is inappropriate because delaying cancer surgery for 6 months allows tumor progression and metastasis - the bleeding risk from surgery generally outweighs the thrombotic risk of temporarily modifying DAPT.

Key strategy: In perioperative DAPT management, remember that aspirin is usually continued (lower bleeding risk, high cardiovascular benefit), while P2Y12 inhibitors like clopidogrel are held 5-7 days before major surgery. Cancer surgery timing takes priority over completing full DAPT duration, but some antiplatelet protection should be maintained.

For patients with a minor ischemic stroke (NIHSS ≤3) or high-risk TIA, dual antiplatelet therapy (DAPT) with aspirin and clopidogrel is recommended for a short duration to reduce the risk of recurrent stroke. Evidence from the CHANCE and POINT trials supports continuing DAPT for 21 to 90 days. After this period, DAPT should be discontinued and single antiplatelet therapy (e.g., aspirin) should be continued long-term to minimize bleeding risk.

For secondary stroke prevention, current AHA/ASA guidelines recommend a target blood pressure of <130/80 mmHg. This patient's blood pressure is above this goal. Therefore, her antihypertensive regimen should be intensified. This can be achieved by increasing the dose of her current medication (amlodipine) or by adding a second agent, such as a thiazide diuretic or an ACE inhibitor/ARB.

This patient has high-grade (70-99%) symptomatic carotid stenosis, with the TIA localizing to the affected artery. For such patients, carotid endarterectomy (CEA) in addition to optimal medical therapy has been shown to significantly reduce the risk of subsequent stroke. Carotid artery stenting (CAS) is an alternative, but in patients over age 70, CEA is generally preferred due to a lower periprocedural risk of stroke compared to CAS.

Multiple randomized controlled trials (e.g., RESPECT, CLOSE) have demonstrated that in patients aged 18-60 with a cryptogenic stroke attributed to a PFO, percutaneous PFO closure combined with antiplatelet therapy is superior to medical therapy (either antiplatelet or anticoagulant) alone in preventing recurrent stroke. Given this patient's age and clinical presentation, PFO closure is the recommended intervention.

This patient experienced an ischemic stroke in the setting of atrial fibrillation, indicating a cardioembolic source. For secondary stroke prevention in patients with atrial fibrillation, oral anticoagulation is markedly superior to antiplatelet therapy. A direct oral anticoagulant (DOAC) like apixaban is preferred over warfarin due to a better safety profile and ease of use. Aspirin should be discontinued when an anticoagulant is started for this indication to minimize bleeding risk, unless there is another compelling reason for it (e.g., recent coronary stent).

This patient's symptoms are classic for central post-stroke pain (CPSP), a neuropathic pain syndrome resulting from a lesion in the central nervous system, commonly the thalamus. First-line treatments for CPSP include tricyclic antidepressants (like amitriptyline) or anticonvulsants (like gabapentin or pregabalin). Opioids, NSAIDs, and acetaminophen are generally not effective for this type of pain.

When you encounter stroke prevention questions, focus on evidence-based dietary interventions that address multiple cardiovascular risk factors simultaneously, especially in patients with metabolic syndrome features like this obese, hypertensive patient.

The Mediterranean diet with sodium restriction (D) has the strongest evidence for stroke prevention. Large randomized controlled trials, particularly PREDIMED, demonstrated that a Mediterranean dietary pattern rich in olive oil, nuts, fruits, vegetables, whole grains, and fish reduces stroke risk by approximately 30%. The addition of sodium restriction is crucial for this hypertensive patient, as high sodium intake directly contributes to elevated blood pressure, a major modifiable stroke risk factor. This diet addresses multiple pathways: reducing inflammation, improving endothelial function, lowering blood pressure, and optimizing lipid profiles.

Option A is incorrect because ketogenic diets lack robust evidence for stroke prevention and may actually increase cardiovascular risk in some patients due to potential increases in LDL cholesterol and limited long-term safety data.

Option B fails because focusing solely on dietary cholesterol restriction is outdated and overly narrow. Dietary cholesterol has minimal impact on blood cholesterol for most people, and this approach ignores other important risk factors.

Option C is wrong because high-protein, low-fat diets emphasizing lean meats don't address the comprehensive nutritional needs for stroke prevention and may lack the anti-inflammatory compounds found in plant-rich diets.

For USMLE Step 3, remember that evidence-based medicine drives recommendations. When asked about dietary interventions for cardiovascular disease prevention, Mediterranean diet consistently shows the strongest clinical trial evidence across multiple outcomes.

When you encounter a patient requiring both secondary stroke prevention and treatment for a bleeding peptic ulcer, you're balancing two competing risks: thrombotic events versus bleeding complications. The key is understanding that antithrombotic therapy remains essential for stroke prevention, but the bleeding risk can be mitigated.

This patient needs continued antiplatelet therapy for secondary stroke prevention after his lacunar stroke. The bleeding duodenal ulcer was likely caused by aspirin combined with H. pylori infection. The solution isn't to abandon stroke prevention, but to address the underlying causes of bleeding while maintaining antithrombotic protection.

Option D is correct because it treats H. pylori (eliminating a major ulcer risk factor), adds a proton pump inhibitor (reducing gastric acid and ulcer recurrence), and resumes the necessary aspirin for stroke prevention. This approach addresses both conditions appropriately.

Option A is dangerous because permanently stopping antithrombotic therapy leaves the patient unprotected against recurrent stroke, which poses a greater long-term risk than managed bleeding.

Option B substitutes warfarin unnecessarily. Warfarin isn't superior to aspirin for lacunar stroke prevention and actually carries higher bleeding risk, making this substitution counterproductive.

Option C switches to clopidogrel, which offers no proven advantage over aspirin for this indication and is more expensive. While treating H. pylori is appropriate, the antiplatelet switch isn't warranted.

Remember: In secondary stroke prevention, don't let bleeding complications derail necessary antithrombotic therapy. Instead, optimize the patient's condition to safely continue the therapy they need.

The patient is exhibiting symptoms of post-stroke cognitive impairment, consistent with vascular dementia. While aggressive management of vascular risk factors (hypertension, diabetes, dyslipidemia) is the cornerstone of preventing progression, symptomatic management is also important. The most appropriate initial intervention is non-pharmacologic. Cognitive rehabilitation and occupational therapy can help the patient develop compensatory strategies to improve functional independence and safety. While medications like donepezil have a modest and sometimes controversial role, rehabilitation is a key first step.